Unleash Immuno Oncolytics, founded with the mission to revolutionize cancer treatment, focuses on developing advanced oncolytic virus immunotherapy products. The company's core vision is to harness the immune system's power to combat cancer more effectively. Their flagship product, UIO-512, is an oncolytic adenovirus designed to target both malignant cells and tumor-associated stromal cells, offering a dual-action approach to cancer therapy. Unleash IO primarily targets the oncology market, addressing the significant challenges of treating metastatic disease.
Notable figures associated with Unleash Immuno Oncolytics include experienced professionals in the fields of immunology and oncology, contributing to the company's innovative edge. The company has garnered attention from key investors in the biotech sector, supporting its research and development efforts. Unleash IO's significant achievements include demonstrating high specificity and efficacy of their products in animal models and human tissue samples. Their work has had a considerable impact on advancing cancer immunotherapy, positioning them as a promising player in the fight against cancer.
Unleash Immuno Oncolytics' most recent funding round was for $3M (USD) in February 2018.
As of Feb 19, 2018, Unleash Immuno Oncolytics has disclosed funding of $3M (USD).

IconOVir Bio
iconovir.com

Dnatrix
dnatrix.com

Adze Biotechnology
adzebiotech.com

Imanis Life Sciences
imanislife.com
OncoMyx Therapeutics
oncomyx.com

Toragen
toragen.com

VerImmune
verimmune.com

Seneca Therapeutics

Oncolyze
oncolyze.com

BioEclipse Therapeutics
bioeclipse.com
Cynvec
cynvec.com

Vesselon
vesselon.com

ImmunoMet Therapeutics
immunomet.com

Istari Oncology
istarioncology.com

Immunophotonics

Virion Therapeutics
viriontx.com

Aulos Bioscience
aulosbio.com

Immunomic Therapeutics
immunomix.com

Immunitas Therapeutics
immunitastx.com

INmune Bio
inmunebio.com